Prospective screening for HLA-B*15:02 significantly decreased the incidence of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) (p<0.001)
|HLA-B*15:02-positive patients who did not take carbamazepine (n=367)||HLA-B*15:02-negative patients who received carbamazepine (n=4120)||Historical incidence|
|Number with SJS/TEN||0||0||10|
Mild, transient rash and itching developed in 211 subjects - 5 were HLA-B*15:02 positive. More severe cutaneous symptoms developed in 7 subjects - 1 was HLA-B*15:02 positive (urticaria).